Was anyone really backing azathioprine against vitamin R in relapsed ANCA-associated vasculitis? Catch-up on the RCT here.
Summary of the CAPTIVATE platform which will be a twitter spaces discussion
This week, we will discuss a registry trial: can a nationwide nudge fix a CKD treatment gap?
This week, we will discuss a pediatric nephrology trial: is tacrolimus superior to MMF in FRNS and SDNS?
This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.
Was anyone really backing azathioprine against vitamin R in relapsed ANCA-associated vasculitis? Catch-up on the RCT here.
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) June 3, 2023
✳️10 tweet #NephJC catch-up ✳️
🌟Let’s recap the RITAZAREM trial - a rematch between Rituximab and Azathioprine as the maintenance agent of choice in relapsed ANCA-associated vasculitis.
🌟Have we witnessed the ultimate triumph of Rituximab? pic.twitter.com/HbFKhe6MKc